Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752970 | 1.00 | BRAF (0.45) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL24752974 | 0.96 | BRAF (0.43) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL30120432 | 0.90 | BRAF (0.51) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL30120168 | 0.89 | BRAF (0.46) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL26591137 | 0.89 | BRAF (0.46) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL29196989 | 0.89 | GPR119 (0.46) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL30120453 | 0.89 | GPR119 (0.46) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL31548449 | 0.87 | CYP2D6 (0.45) | BRAFBTKCYP2D6GPR119ENPP2 | |
| SCHEMBL24542773 | 0.86 | BRAF (0.47) | BRAFBTKGPR119ENPP2IRAK4 | |
| SCHEMBL30120157 | 0.86 | BRAF (0.47) | BRAFBTKGPR119ENPP2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |